Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 3 art units • 5 examiners • 0 of 9 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Axsome Therapeutics Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 4 examiners and 3 art units, indicating some concentration within a relatively contained examination structure. The portfolio can support coordinated technical and claim strategy, but responses still need to reflect the assigned examiner and art unit.
HOWELL, THEODORE R is the busiest examiner, with 5 pending matters. This is the clearest concentration in the profile, making that examiner’s prosecution positions especially relevant to docket planning. Counsel should review those matters together for recurring claim interpretation and prior-art themes, while avoiding assumptions that the same approach will apply to the remaining assignments.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| Double-patenting only | 3 (33%) |
| Double-patenting + other | 3 (33%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 5 | 66.9% | +25.1% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| THOMAE, EVAN GODFREY | 1 | — | — |
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19236838 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 77d overdue |
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 67d overdue |
| 18366992 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 44d overdue |
| 18503996 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 19d |
| 18512551 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 26d |
| 19646069 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | LEE, WILLIAM Y | — |
| 18636093 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | VALENROD, YEVGENY | — |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 6 |
| 1623 | 2 |
| 3786 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19646069 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | LEE, WILLIAM Y | 1623 | §103DP | Non-Final OA | — | Pending | Apr 13, 2026 |
| 19236838 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | §103 | Non-Final OA | 77d overdue | Pending | Jun 12, 2025 |
| 19169261 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 67d overdue | Pending | Apr 03, 2025 |
| 18950743 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | THOMAE, EVAN GODFREY | 1623 | §103§112DP | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18636093 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | VALENROD, YEVGENY | 1628 | §103DP | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | 3786 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18512551 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | DP | Final Rejection | 26d | Pending | Nov 17, 2023 |
| 18503996 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | DP | Final Rejection | 19d | Pending | Nov 07, 2023 |
| 18366992 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | HOWELL, THEODORE R | 1628 | DP | Final Rejection | 44d overdue | Pending | Aug 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAxsome Therapeutics Inc. has 9 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Theodore R Howell has the most, with 5 of Axsome Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
